Cargando…
Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors
BACKGROUND AND OBJECTIVE: Population pharmacokinetic analysis explored the pharmacokinetics of sunitinib and its primary active metabolite, SU012662, in children and evaluated the sunitinib dose(s) that produce comparable plasma exposures to adults receiving the approved daily dose. METHODS: Data we...
Autores principales: | Wang, Erjian, DuBois, Steven G., Wetmore, Cynthia, Verschuur, Arnauld C., Khosravan, Reza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093178/ https://www.ncbi.nlm.nih.gov/pubmed/33852135 http://dx.doi.org/10.1007/s13318-021-00671-7 |
Ejemplares similares
-
Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020) -
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021) -
Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
por: Verschuur, Arnauld C., et al.
Publicado: (2019) -
Population
Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients
with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016) -
Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()
por: Chen, Yen-Yang, et al.
Publicado: (2014)